newsfilter
← Latest News
GlobeNewswire·

Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030

  • Teva Pharmaceutical Industries Ltd. hosted its first-ever R&D Day on November 11, 2026, to outline its growth strategy & ambition to generate $6–7 billion in innovative medicines revenue by 2030.
  • Since launching the Pivot to Growth strategy in 2023, the company has more than doubled revenue from innovative medicines & returned to an investment grade credit rating.
  • CEO Richard Francis highlighted a pipeline with over $10 billion in peak sales potential & a goal to launch one innovative medicine annually through 2030.
  • Key pipeline updates include Anti-IL-15 meeting primary endpoints in Celiac disease Phase 2a studies with Phase 2b expected in late 2027, & TEV-408 advancing to Phase 2/3 in vitiligo.
  • The investigational asset Anti-PD-1/IL-2 ATTENUKINE is in Phase 1 for advanced cancer, showing early efficacy signals, while next-generation antibodies target asthma & inflammatory bowel disease.
  • Innovations now comprise more than 20% of total revenue, with gross margins improving to approximately 55% as of Q3 2026.
  • Three key innovative products (AUSTEDO, AJOVY, UZEDY) are projected to grow over 125% by the end of 2026, following the recent launch of WELTRUZA.
  • Financial outlook through 2030 includes targets for innovative gross margins above 75%, total revenue mid-single-digit growth, free cash flow exceeding $3.5 billion, & leverage reduced to 2.0x net debt to adjusted EBITDA by end-2027.
  • The company reports over $6 billion in free cash flow generated from 2023 to 2025, supporting reinvestment in the pipeline & business development.
  • A live webcast of the event was available on Teva's Investor Relations website, followed by a dedicated media Q&A session with executive leadership.
Company
Teva Pharmaceutical Industries Ltd
Keywords
NYSE:TEVA, Teva Pharmaceutical Industries Ltd, Teva Pharmaceutical, TEVA, R&D Day, innovative pipeline, Pivot to Growth, High velocity biopharma, Proven science, Richard Francis